PRIME-ROSE - Outcome
PRIME-ROSE activities are organized in eight work packages. Here we will publish results from each of the work packages regularly, including white papers, reports, scientific publications, podcast episodes and press releases. Stay tuned and follow the progress of the project.
WP1
Data Aggregation
WP1 will build a platform to aggregate data from each participating institution. This will constitute the foundation of evidence generation in the project, and the platform will feed the other work packages.
WP2
Control Cohorts
WP2 will generate multiple synthetic control arms and randomise a fixed treatment arm to these. This will allow us to evaluate clinical efficacy and cost effectiveness by established methods.
WP3
Expansion Cohorts
WP3 aims to initiate and run expansion cohorts that are designed based on data from WP1. Moreover, biomarkers and endpoints will be refined in these cohorts to meet clinical needs and develop PCM treatment further.
WP4
Drug Repurposing
WP4 will address early access and off-label reimbursement systems in Europe. This work package will also study disparity and inequality in access to off-label use.
WP5
EU Implementation
WP5 aims to provide additional necessary documentation for local decision makers to assess and implement new drugs based on our results from WP3 and WP4.
WP6
Social Innovation
WP6 collaborates on patient utilities of trial outcomes to provide a better understanding of how certain outcomes impact patients. This ensures that long-term, clinical trials capture outcomes that not only prolong but truly improve the lives of patients.
WP7
Project Management
WP7 will manage the project and coordinate with national PCM initiatives to ensure that scientific progress rapidly benefits patients.
WP8
Dissemination
WP8 is responsible for the stakeholder engagement strategy as well as dissemination of project outputs in an effective, timely and targeted way.
